Finerenone Benefits Patients With T2D, CKD Across CKM Stages

Published Date: 01 Jul 2026

In patients with T2D and CKD, finerenone lowers the risk for adverse cardiovascular and kidney events compared with placebo, regardless of the CKM syndrome stage at baseline.

Read Full News

Latest News

HTTP error: 503HTTP error: 503 HTTP error: 503HTTP error: 503HTTP error: 503

News All Time

HTTP error: 503 HTTP error: 503 HTTP error: 503 HTTP error: 503 HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chromatin organization linked to p53 tumor suppression mechanism

2.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

3.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

4.

New protein target discovered for childhood medulloblastomas

5.

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot